COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma
Treating patients with multiple myeloma in the real world
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML
New CAR T therapy for relapsed and refractory ALL
IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera